Passage Bio, Inc. (PASG)
NASDAQ: PASG · Real-Time Price · USD
0.660
+0.006 (0.92%)
Dec 20, 2024, 4:00 PM EST - Market closed
Passage Bio Employees
Passage Bio had 58 employees as of December 31, 2023. The number of employees decreased by 27 or -31.76% compared to the previous year.
Employees
58
Change (1Y)
-27
Growth (1Y)
-31.76%
Revenue / Employee
n/a
Profits / Employee
-$1,186,207
Market Cap
40.77M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 58 | -27 | -31.76% |
| Dec 31, 2022 | 85 | -48 | -36.09% |
| Dec 31, 2021 | 133 | 59 | 79.73% |
| Dec 31, 2020 | 74 | 54 | 270.00% |
| Dec 31, 2019 | 20 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Achilles Therapeutics | 215 |
| Neuronetics | 203 |
| CASI Pharmaceuticals | 176 |
| ImmuCell | 79 |
| Rallybio | 43 |
| Q32 Bio | 37 |
| Nexalin Technology | 6 |
PASG News
- 6 weeks ago - Passage Bio to Present at Guggenheim Securities Healthcare Innovation Conference - GlobeNewsWire
- 2 months ago - Passage Bio Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Conference - GlobeNewsWire
- 3 months ago - Passage Bio to Present at Chardan's 8th Annual Genetic Medicines Conference - GlobeNewsWire
- 3 months ago - Passage Bio Welcomes Tom Kassberg to Board of Directors - GlobeNewsWire
- 4 months ago - Passage Bio to Present at H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewsWire
- 4 months ago - Passage Bio Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights - GlobeNewsWire
- 5 months ago - Passage Bio Out-licenses Three Pediatric Gene Therapy Programs to GEMMA Biotherapeutics and Enters New Research Collaboration - GlobeNewsWire
- 5 months ago - Passage Bio Announces Positive Feedback from FDA on Expansion of upliFT-D Trial of PBFT02 to Include FTD-C9orf72 Patients - GlobeNewsWire